Akero Therapeutics in the spotlight

Data analysis and coverage of names in the GLP, MASH, fibrosis space

In a prior note, we covered the impact that the GLP-1 drug class would have on related markets. On this note, we’ll focus on NASH (now commonly referred to as MASH - metabolic dysfunction-associated steatohepatitis). This fatty liver disease is caused by excess fat cells. Chronic inflammation causes progressive liver damage, most often associated with o…